Hikma Pharmaceuticals (LON:HIK) Shares Down 14.1% Following Analyst Downgrade

Hikma Pharmaceuticals PLC (LON:HIK) was down 14.1% on Thursday after Berenberg Bank lowered their price target on the stock from GBX 2,510 to GBX 2,300. Berenberg Bank currently has a buy rating on the stock. Hikma Pharmaceuticals traded as low as GBX 1,522 and last traded at GBX 1,522. Approximately 166,325,172 shares changed hands during mid-day trading, an increase of 7,989% from the average daily volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

Several other equities research analysts also recently commented on the stock. Peel Hunt restated a “buy” rating and issued a GBX 2,170 target price on shares of Hikma Pharmaceuticals in a research note on Friday. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,360 price objective on shares of Hikma Pharmaceuticals in a research report on Friday. JPMorgan Chase & Co. cut their price target on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating for the company in a report on Friday. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Hikma Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of GBX 2,416.

Insiders Place Their Bets

In related news, insider Laura Balan Balan acquired 3,500 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was acquired at an average cost of GBX 1,821 per share, with a total value of £63,735. Also, insider Mazen Darwazah bought 315,000 shares of Hikma Pharmaceuticals stock in a transaction on Thursday, November 6th. The shares were bought at an average price of GBX 1,601 per share, for a total transaction of £5,043,150. In the last three months, insiders bought 332,500 shares of company stock worth $533,130,500. 17.77% of the stock is currently owned by company insiders.

Hikma Pharmaceuticals Stock Up 3.9%

The company has a market capitalization of £3.50 billion, a P/E ratio of 9.47, a P/E/G ratio of 2.38 and a beta of 0.41. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82. The firm has a fifty day simple moving average of GBX 1,730.88 and a 200-day simple moving average of GBX 1,893.97.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.